| [1] |
Neavin DR, Liu D, Ray B, et al. The role of the Aryl hydrocarbon receptor (AHR) in immune and inflammatory diseases[J]. Int J Mol Sci, 2018, 19(12): 3851.
|
| [2] |
Wu X, Gu Z, Chen Y, et al. Application of PD-1 blockade in cancer immunotherapy[J]. Comput Struct Biotechnol J, 2019, 17: 661-674.
|
| [3] |
Liu Y, Liang X, Dong W, et al. Tumor-repopulating cells induce PD-1 expression in CD8+ T cells by transferring kynurenine and AhR activation[J]. Cancer Cell, 2018, 33(3): 480-494.
|
| [4] |
Xue P, Fu J, Zhou Y. The Aryl hydrocarbon receptor and tumor immunity[J]. Front Immunol, 2018, 9: 286.
|
| [5] |
Yeung AW, Terentis AC, King NJ, et al. Role of indoleamine 2,3-dioxygenase in health and disease[J]. Clin Sci (Lond), 2015, 129(7): 601-672.
|
| [6] |
Mejía-García A, González-Barbosa E, Martínez-Guzmán C, et al. Activation of AHR mediates the ubiquitination and proteasome degradation of c-Fos through the induction of Ubcm4 gene expression[J]. Toxicology, 2015, 337: 47-57.
|
| [7] |
Ghosh J, Chowdhury AR, Srinivasan S, et al. Cigarette smoke toxins-induced mitochondrial dysfunction and pancreatitis involves Aryl hydrocarbon receptor mediated Cyp1 gene expression: protective effects of resveratrol[J]. Toxicol Sci, 2018, 166(2): 428-440.
|
| [8] |
Moreno-Marín N, Merino JM, Alvarez-Barrientos A, et al. Aryl hydrocarbon receptor promotes liver polyploidization and inhibits PI3K, ERK, and Wnt/β-Catenin signaling[J]. iScience, 2018, 4: 44-63.
|
| [9] |
Hýžd'alová M, Pivnicka J, Zapletal O, et al. Aryl hydrocarbon receptor-dependent metabolism plays a significant role in estrogen-like effects of polycyclic aromatic hydrocarbons on cell proliferation[J]. Toxicol Sci, 2018, 165(2): 447-461.
|
| [10] |
Yang SY, Ahmed S, Satheesh SV, et al. Genome-wide mapping and analysis of Aryl hydrocarbon receptor (AHR)- and Aryl hydrocarbon receptor repressor (AHRR)-binding sites in human breast cancer cells[J]. Arch Toxicol, 2018, 92(1): 225-240.
|
| [11] |
Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 Checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome[J]. Front Pharmacol, 2017, 8:561.
|
| [12] |
Chen L, Han X. Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future[J]. J Clin Invest, 2015, 125(9): 3384-3391.
|
| [13] |
Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses[J]. Immunity, 2007, 27(1): 111-122.
|
| [14] |
Hui E, Cheung J, Zhu J, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition[J]. Science, 2017, 355(6332): 1428-1433.
|
| [15] |
Gianchecchi E, Fierabracci A. Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression[J]. Front Immunol, 2018, 9: 2374.
|
| [16] |
Spranger S, Koblish HK, Horton B, et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment[J]. J Immunother Cancer, 2014, 2: 3.
|
| [17] |
Kolluri SK, Jin UH, Safe S. Erratum to: role of the Aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target[J]. Arch Toxicol, 2017, 91(9): 3209.
|
| [18] |
Garcia-Villatoro EL, DeLuca J, Callaway ES, et al. Effects of high-fat diet and intestinal Aryl hydrocarbon receptor deletion on colon carcinogenesis[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318(3): G451-451, G463.
|
| [19] |
Zhu XY, Xia HG, Wang ZH, et al. In vitro and in vivo approaches for identifying the role of Aryl hydrocarbon receptor in the development of nonalcoholic fatty liver disease[J]. Toxicol Lett, 2020, 319: 85-94.
|
| [20] |
Ngui I, Perera AP, Eri R. Does NLRP3 inflammasome and Aryl hydrocarbon receptor play an interlinked role in bowel inflammation and colitis-associated colorectal cancer?[J]. Molecules, 2020, 25(10): 2427.
|
| [21] |
Baker JR, Sakoff JA, McCluskey A. The Aryl hydrocarbon receptor (AhR) as a breast cancer drug target[J]. Med Res Rev, 2020, 40(3): 972-1001.
|
| [22] |
Jin UH, Kim SB, Safe S. Omeprazole inhibits pancreatic cancer cell invasion through a nongenomic Aryl hydrocarbon receptor pathway[J]. Chem Res Toxicol, 2015, 28(5): 907-918.
|
| [23] |
Toulmonde M, Penel N, Adam J, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: A phase 2 clinical trial[J]. JAMA Oncol, 2018, 4(1): 93-97.
|
| [24] |
Wei ZF, Lv Q, Xia Y, et al. Norisoboldine, an anti-arthritis alkaloid isolated from radix linderae, attenuates osteoclast differentiation and inflammatory bone erosion in an Aryl hydrocarbon receptor-dependent manner[J]. Int J Biol Sci, 2015, 11(9): 1113-1126.
|
| [25] |
Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the Aryl hydrocarbon receptor[J]. Nature, 2008, 453(7191): 65-71.
|
| [26] |
Goudot C, Coillard A, Villani AC, et al. Aryl hydrocarbon receptor controls monocyte differentiation into dendritic cells versus macrophages[J]. Immunity, 2017, 47(3): 582-596. e6.
|
| [27] |
Smits J, Ederveen T, Rikken G, et al. Targeting the cutaneous microbiota in atopic dermatitis by coal tar via AHR-dependent induction of antimicrobial peptides[J]. J Invest Dermatol, 2020, 140(2): 415-424. e10.
|
| [28] |
Kanai T, Naganuma M. Reply[J]. Gastroenterology, 2018, 155(2): 578-579.
|
| [29] |
Wang LT, Chiou SS, Chai CY, et al. Intestine-specific homeobox gene ISX integrates IL6 signaling, tryptophan catabolism, and immune suppression[J]. Cancer Res, 2017, 77(15): 4065-4077.
|
| [30] |
Wang GZ, Zhang L, Zhao XC, et al. The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy[J]. Nat Commun, 2019, 10(1): 1125.
|
| [31] |
Xie FT, Cao JS, Zhao J, et al. IDO expressing dendritic cells suppress allograft rejection of small bowel transplantation in mice by expansion of Foxp3+ regulatory T cells[J]. Transpl Immunol, 2015, 33(2): 69-77.
|
| [32] |
Li C, Liu T, Zhao N, et al. Dendritic cells transfected with indoleamine 2,3-dioxygenase gene suppressed acute rejection of cardiac allograft[J]. Int Immunopharmacol, 2016, 36: 31-38.
|
| [33] |
Sun X, Gong ZJ, Wang ZW, et al. IDO-competent-DCs induced by IFN-γ attenuate acute rejection in rat liver transplantation[J]. J Clin Immunol, 2012, 32(4): 837-847.
|
| [34] |
Saha A, Aoyama K, Taylor PA, et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality[J]. Blood, 2013, 122(17): 3062-3073.
|
| [35] |
Hossain MS, Kunter GM, El-Najjar VF, et al. PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients[J]. PLoS One, 2017, 12(9): e0184254.
|
| [36] |
Curran CS, Gupta S, Sanz I, et al. PD-1 immunobiology in systemic lupus erythematosus[J]. J Autoimmun, 2019, 97: 1-9.
|
| [37] |
Inoue H, Mishima K, Yamamoto-Yoshida S, et al. Aryl hydrocarbon receptor-mediated induction of EBV reactivation as a risk factor for Sjgren’s syndrome[J]. J Immunol, 2012, 188(9): 4654-4662.
|